MIRA
MIRA Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-09
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.37
P/S
0.00
EV/EBITDA
-3.62
DCF Value
$0.27
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-646.3%
ROA
-288.4%
ROIC
-101.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-6.0M | $0.03 |
| FY 2025 | $0.00 | $-10.4M | $-1.35 |
| Q3 2025 | $0.00 | $-22.7M | $-1.18 |
| Q2 2025 | $0.00 | $-1.5M | $-0.09 |
Analyst Ratings
View AllConsensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.94
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.